SVA SINOVAC BIOTECH LTD

Price Chart

Executive Summary

Sinovac filed its long-delayed FY2025 annual report (20-F) on June 5, 2026, just days after receiving a Nasdaq delist notice for the same failure to file. The filing reveals deep operational deterioration: a net loss attributable to shareholders of -$59.7M (vs. +$90.9M profit in 2024), driven by $137.2M in PP&E impairments, $65.6M in goodwill/IPR&D write-offs from the Sinovac Chengdu acquisition, and a $109.8M currency loss. Revenue grew modestly to $386.0M (+6.8% YoY) on higher varicella/influenza export sales, but gross margin improvement to 67.9% was offset by operating losses of -$490.1M. A massive $3.96B dividend upstreamed from subsidiaries to Sinovac Antigua and partially distributed ($55/share special dividend) almost entirely drained retained earnings ($6.84B to $2.82B). Material weaknesses in internal controls persist. The board is still contested via ongoing Antigua SSM proceedings. Trading remains halted since Feb 2019.

Actionable Insight

Key Facts

• Net loss attributable to common shareholders of -$59.7M in FY2025 vs. net income of +$90.9M in FY2024
• Revenue grew 6.8% to $386.0M in FY2025 from $361.4M in FY2024, driven by varicella/influenza export sales
• Loss on PP&E impairment surged to $137.2M in FY2025 (vs. $30.3M in FY2024); goodwill impairment of $15.7M and IPR&D impairment of $49.8M recorded
• Cash dividend of $55.00/share declared (special dividend totaling ~$3.96B upstreamed from subsidiaries), paid $3.30B in 2025 with $657.9M deferred payable
• Retained earnings collapsed from $6.84B at Dec 2024 to $2.82B at Dec 2025
• Material weaknesses in internal controls remain unresolved — governance/financial close/ITGC weaknesses persist
• Trading halted since Feb 2019; received Nasdaq delist determination on May 22, 2026 for late filing
• Ongoing Antigua SSM Proceedings contest board legitimacy; PIPE share litigation/arbitration unresolved
• Auditor changed to Zhonghua; prior auditor (Grant Thornton) withdrew opinions for FY2021-2023 citing uncertainty over board actions

Financial Impact

Net loss of $59.7M attributable to common shareholders (vs. +$90.9M profit prior year); $386.0M revenue (+6.8%); $262.1M pre-tax loss; $137.2M PP&E impairment; $65.6M goodwill/IPR&D impairment

Risk Factors

• Nasdaq panel hearing outcome uncertain; further delist if hearing lost
• Ongoing Antigua SSM board legitimacy challenge (preliminary issues trial May-June 2026) creates governance paralysis
• PIPE litigation/arbitration could result in invalidation of 11.8M shares or cash escrow release
• Dividend withholding tax on Sinovac Hong Kong changed to 10% retroactively, increasing cash tax burden
• Cash and restricted cash at $1.16B but $657.9M is deferred dividend payable and $662.9M is escrowed for PIPE dispute
• No annual shareholder meeting held since Feb 2018 — governance vacuum persists

Market Snapshot

Documents Analyzed

This report is based on 9 SEC documents filed with EDGAR.

US Market Status